MMSI Stock Forecast & Price Target

Merit Medical Systems, Inc. has demonstrated a strong financial performance, with gross margins expanding from 48.8% in FY22 to a forecasted 53.4% in 2025, reflecting a notable 460 basis point improvement. The company reported an overall revenue increase of approximately 11%, driven primarily by its Cardiovascular segment, which also saw revenue growth of about 11% as reported. Additionally, the increase in physician reimbursement for certain procedures by around 27% and the robust performance of the Endoscopy segment, which grew 15% to $20.1 million, further reinforces the positive outlook for the company.

Merit Medical Systems Inc. has reported disappointing OEM revenue of $48.1 million, falling short of expectations of $58.3 million, which highlights potential weaknesses in their revenue growth strategies. The company faces significant risks, including worse-than-expected margin performance and free cash flow, exacerbated by slower growth in its largest overseas market, China, which is adversely affected by volume-based procurement (VBP) headwinds and broader macroeconomic pressures. Additionally, there are concerns about the sustainability of operating margins, as the company may struggle to implement price increases across its product portfolio amidst declining sales and unsuccessful new product launches.